New cell therapy battles bacterial infections
For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics, which are susceptible to resistance and are limited accessing infections.
VCT-001 is an allogeneic cell therapy to be given with standard of care antibiotic regimens to successfully treat infections. Validus is commercializing a proprietary activation process making mesenchymal stem cells capable of healing these resistant infections. Activated stem cells have been shown to both boost the natural immune system and directly kill bacteria.